Literature DB >> 15168151

Bone mineral density in children with familial Mediterranean fever.

Ali Duzova1, Fatih Ozaltin, Alev Ozon, Nesrin Besbas, Rezan Topaloglu, S Ozen, A Bakkaloglu.   

Abstract

The aim of this study was to evaluate bone mineral content (BMC), serum and urinary bone turnover parameters in patients with familial Mediterranean fever (FMF), an autosomal recessive disease characterized by recurrent episodes of inflammation of serous membranes. Demographic characteristics and MEFV mutations were defined in 48 children diagnosed with FMF (23 F, 25 M; median age 7.0 years (3.0-10.0)). We evaluated the blood counts, acute-phase proteins and serum and urinary bone turnover parameters during attack-free periods. The BMC and BA (bone area) of vertebrae L1-L4 were measured by DEXA. Thirty-eight age-, sex- and ethnicity-matched healthy children constituted the control group. Mean L1-L4 BMC in Group I (patients with two mutations) and II (patients with no or single mutations) were 15.49+/-5.99 g and 15.68+/-4.89 g, respectively, both significantly lower than the mean L1-L4 BMC of control patients, which was 19.59+/-6.7 g (p<0.05). Mean L1-L4 BMD in Group I, Group II and the control group were 0.466+/-0.066 g/cm(2), 0.487+/-0.085 g/cm(2 )and 0.513+/-0.079 g/cm(2), respectively. Mean z-scores in Group I, Group II and the control group were -1.87+/-0.74, -1.55+/-0.92 and -1.39+/-0.84, respectively. Mean L1-L4 BMD and z-score of Group I were lower than in the control group (p<0.05). ESR and SAA (serum amyloid A) levels were higher in Group I patients: 28.3+/-14.5 mm/h and 350+/-62 mg/l in Group I; and 20.5+/-11.7 mm/h and 190+/-68 mg/l in Group II, respectively. In conclusion, FMF patients had lower BMC, BMD and z-scores than a control group. We suggest that decreased BMD, BMC and z-score in FMF patients may be secondary to subclinical inflammation.

Entities:  

Mesh:

Year:  2004        PMID: 15168151     DOI: 10.1007/s10067-004-0874-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Acute phase response and evolution of familial Mediterranean fever.

Authors:  M Tunca; G Kirkali; M Soytürk; S Akar; M B Pepys; P N Hawkins
Journal:  Lancet       Date:  1999-04-24       Impact factor: 79.321

Review 2.  Familial Mediterranean fever. A survey of 470 cases and review of the literature.

Authors:  E Sohar; J Gafni; M Pras; H Heller
Journal:  Am J Med       Date:  1967-08       Impact factor: 4.965

3.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-10       Impact factor: 3.791

4.  Peripheral bone mass is not affected by winter vitamin D deficiency in children and young adults from Ushuaia.

Authors:  M B Oliveri; A Wittich; C Mautalen; A Chaperon; A Kizlansky
Journal:  Calcif Tissue Int       Date:  2000-09       Impact factor: 4.333

5.  Mutations in the MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever.

Authors:  C Dodé; C Pêcheux; C Cazeneuve; D Cattan; M Dervichian; M Goossens; M Delpech; S Amselem; G Grateau
Journal:  Am J Med Genet       Date:  2000-06-05

6.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

7.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

8.  Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.

Authors:  A Duzova; A Bakkaloglu; N Besbas; R Topaloglu; S Ozen; F Ozaltin; Y Bassoy; E Yilmaz
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

9.  Serum 25-hydroxyvitamin D levels and bone mineral density in 16-20 years-old girls: lack of association.

Authors:  J O Kristinsson; O Valdimarsson; G Sigurdsson; L Franzson; I Olafsson; L Steingrimsdottir
Journal:  J Intern Med       Date:  1998-05       Impact factor: 8.989

10.  Body mass index reference curves for the UK, 1990.

Authors:  T J Cole; J V Freeman; M A Preece
Journal:  Arch Dis Child       Date:  1995-07       Impact factor: 3.791

View more
  7 in total

1.  Bone mineral density in familial Mediterranean fever.

Authors:  Neslihan Berkdemir Siverekli; Ozlem Sahin; Soner Senel; Emrullah Hayta; Ece Kaptanoglu; Hasan Elden
Journal:  Rheumatol Int       Date:  2011-07-08       Impact factor: 2.631

Review 2.  Chronic inflammation in FMF: markers, risk factors, outcomes and therapy.

Authors:  Ilan Ben-Zvi; Avi Livneh
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

3.  Bone mineral density in patients with familial Mediterranean fever.

Authors:  Kadir Yildirim; Saliha Karatay; Ramazan Cetinkaya; Hulya Uzkeser; Akin Erdal; Ilyas Capoglu; Fazile Hatipoglu Erdem
Journal:  Rheumatol Int       Date:  2009-05-16       Impact factor: 2.631

4.  Decreased bone mineral density in adult familial Mediterranean fever patients: a pilot study.

Authors:  Elif Suyani; Mehmet Akif Ozturk; Serpil Muge Deger; Mehmet D Demirag; Berna Goker; Seminur Haznedaroglu
Journal:  Clin Rheumatol       Date:  2008-06-14       Impact factor: 2.980

5.  Cephalometric evaluation of children with familial Mediterranean fever.

Authors:  Ahmet Yalcin Gungor; Vefik Arica; Ozge Gungor; Murat Tutanc
Journal:  Angle Orthod       Date:  2011-11-29       Impact factor: 2.079

6.  Serum bone markers levels and bone mineral density in familial mediterranean Fever.

Authors:  Teoman Aydın; Ozgur Taspınar; Yildiz Akbal; Celaleddin Peru; Mustafa Guler; Omer Uysal; M Cengiz Yakıcıer
Journal:  J Phys Ther Sci       Date:  2014-09-17

7.  Osteoporosis in Systemic Autoinflammatory Diseases: A Case-Control Study.

Authors:  Sara Bindoli; Giulio Franceschet; Paola Galozzi; Martina Zaninotto; Valentina Camozzi; Paolo Sfriso
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-18       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.